Journal Article

DKFZ-2022-02502

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.

Giardiello, D. ; Hooning, M. J. ; Hauptmann, M. ; Keeman, R. ; Heemskerk-Gerritsen, B. A. M. ; Becher, H. ; Blomqvist, C. ; Bojesen, S. E. ; Bolla, M. K. ; Camp, N. J. ; Czene, K. ; Devilee, P. ; Eccles, D. M. ; Fasching, P. A. ; Figueroa, J. D. ; Flyger, H. ; García-Closas, M. ; Haiman, C. A. ; Hamann, U.DKFZ* ; Hopper, J. L. ; Jakubowska, A. ; Leeuwen, F. E. ; Lindblom, A. ; Lubiński, J. ; Margolin, S. ; Martinez, M. E. ; Nevanlinna, H. ; Nevelsteen, I. ; Pelders, S. ; Pharoah, P. D. P. ; Siesling, S. ; Southey, M. C. ; van der Hout, A. H. ; van Hest, L. P. ; Chang-Claude, J.DKFZ* ; Hall, P. ; Easton, D. F. ; Steyerberg, E. W. ; Schmidt, M. K.

2022
BioMed Central London

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s13058-022-01567-3

Abstract: Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow-up and including additional risk factors.We included data from 207,510 invasive breast cancer patients participating in 23 studies. In total, 8225 CBC events occurred over a median follow-up of 10.2 years. In addition to the previously included risk factors, PredictCBC-2.0 included CHEK2 c.1100delC, a 313 variant polygenic risk score (PRS-313), body mass index (BMI), and parity. Fine and Gray regression was used to fit the model. Calibration and a time-dependent area under the curve (AUC) at 5 and 10 years were assessed to determine the performance of the models. Decision curve analysis was performed to evaluate the net benefit of PredictCBC-2.0 and previous PredictCBC models.The discrimination of PredictCBC-2.0 at 10 years was higher than PredictCBC with an AUC of 0.65 (95% prediction intervals (PI) 0.56-0.74) versus 0.63 (95%PI 0.54-0.71). PredictCBC-2.0 was well calibrated with an observed/expected ratio at 10 years of 0.92 (95%PI 0.34-2.54). Decision curve analysis for contralateral preventive mastectomy (CPM) showed the potential clinical utility of PredictCBC-2.0 between thresholds of 4 and 12% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers.Additional genetic information beyond BRCA1/2 germline mutations improved CBC risk prediction and might help tailor clinical decision-making toward CPM or alternative preventive strategies. Identifying patients who benefit from CPM, especially in the general breast cancer population, remains challenging.

Keyword(s): BCAC ; BRCA1/2 germline mutation ; Breast Cancer Association Consortium ; Breast cancer genetic predisposition ; Clinical decision-making ; Contralateral breast cancer ; Contralateral preventive mastectomy ; Polygenic risk score ; Prediction performance ; Risk prediction

---

Contributing Institute(s):

1. B070 Funktionelle Genomanalyse (B070)
2. Molekulargenetik des Mammakarzinoms (B072)
3. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Article Processing Charges ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---